Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

July 31, 2010

Study Completion Date

June 30, 2011

Conditions
Pancreatic Cancer
Interventions
GENETIC

Rexin-G

Dosing Schedule: 1 x 10e11 cfu 2 times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.

GENETIC

Rexin-G

Dosing Schedule: 1 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.

GENETIC

Rexin-G

Dosing Schedule: 2 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.

GENETIC

Rexin-G

Dose Schedule: 3 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has less than Grade 1 or less toxicity.

GENETIC

Rexin-G

Dosing Schedule: 4 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.

Trial Locations (3)

10003

Bruckner Oncology, New York

90403

Sarcoma Oncology Center, Santa Monica

91108

Epeius Clinical Research Unit, San Marino

Sponsors
All Listed Sponsors
lead

Epeius Biotechnologies

INDUSTRY